Business Wire

Temenos Named a Leader in Digital Wealth Management Platforms by Independent Research Firm

Share

Temenos (SIX: TEMN), the cloud banking platform, has been named a leader in The Forrester Wave™: Digital Wealth Management Platforms (DWMP) for Q1 2022.

Temenos received the highest scores in the strategy and current offering categories. The report states, “Temenos excels in most areas of product functionality…”, and “its innovation hub focuses on explainable AI/ML; environmental, social, and governance (ESG) capabilities; digital assets; and advanced analytics”.

The report, authored by Vijay Raghavan, Senior Analyst, Forrester, states: “Temenos’ wealth platform offers broad, off-the-shelf business capabilities along with access to a broad array of third-party fintech solutions. […] Temenos is a good choice for financial institutions worldwide looking for broad business capabilities, strong data and analytics, and a vendor with access to a global partner community and large marketplace of fintech solutions through its Temenos Exchange platform.”

According to the Forrester report, “Temenos stands out for its end-to-end digital wealth management capabilities. As one of the most established vendors in the DWMP space, Temenos’ knowledge of different markets has given it a diverse customer base in Europe, APAC, the Middle East, and Latin America, with a target of increasing market share in North America. Temenos excels in most areas of product functionality and has a roadmap and planned enhancements to ensure they will continue to do so.”

The Forester Wave™ evaluates the 12 most significant digital wealth management platform vendors against 27 criteria according to their current offering, strategy and market presence. Temenos received the highest possible score for various categories of the evaluation, including the Customer Experience, Execution Roadmap, Partner Ecosystem, and Planned Enhancements categories.

Max Chuard, Chief Executive Officer, Temenos, said: “We are proud of our leadership in this Forrester Wave, which is a testament to our continued investment in wealth management technology. With narrowing margins in retail, banks are focusing on wealth management in search of higher returns and business model diversification. The industry is also seeing a rapid change with a global generational transfer of wealth, steady growth of high-net-worth individuals, new asset classes, and new regulations. With superior digital customer experience, hyper-personalized services and highly automated processes powered by Temenos, these trends present real opportunities for wealth management firms to retain customers and attract a new generation of investors.”

Temenos believes that this position as a leader reflects Temenos’ commitment to wealth management and its global success serving some of the world’s largest wealth management firms. With Temenos Wealth solutions, banks can differentiate with hyper-personalized digital and human customer interactions. At the same time, wealth management firms can drive efficiencies through core automation and cloud technology.

– Ends –

About Temenos

Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2 billion banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.

Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.

For more information, please visit www.temenos.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jessica Wolfe & Scott Rowe
Temenos Global Public Relations
Tel: +1 610 232 2793 & +44 20 7423 3857
Email : press@temenos.com

Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting26.5.2022 12:00:00 CEST | Press release

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its oncology portfolio will be presented at the upcoming European Hematology Association 2022 (EHA2022) Congress (June 9-17; virtual and in Vienna). “We are committed to advancing science that can lead to solutions for patients with serious unmet medical needs, including those with cancer,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “For that reason, we look forward to convening with the oncology community and presenting data from across our portfolio, including both Incyte-led and partnered programs.” Key abstracts accepted by EHA include: Oral Presentation Long-term Efficacy and Safety Results from an Ongoing Open-Label Phase 2 Study of Parsaclisib for the Treatment of Autoimmune Hemolytic Anemia (AIHA) (Abstract #S286. Session: Transfusion and Autoimmune Hemolytic Anemia. Session Time: Friday, June 10, 11:30 a.m. - 12:45 p.m.) Poster Presentations A Real-World Evaluation of the Association

500 Billion Gallons of Water Prevented from Flooding Communities in 2021, Using Xylem Technology26.5.2022 12:00:00 CEST | Press release

Solutions from global water technology company Xylem (NYSE:XYL), helped prevent more than 500 billion gallons of polluted water from flooding communities in 2021, according to its annual Sustainability Report. The report highlights the Company’s work with customers and partners to solve the world’s greatest water challenges. It also details Xylem’s progress to reduce its operational footprint, including cutting Scope 1 and 2 greenhouse gas (GHG) emission intensity by 12 percent and water use by 22 percent, versus 2019. “It’s a great privilege to have a leading portfolio of technologies and services to help our customers and communities solve the water challenges so central to a more sustainable world,” said Patrick Decker, president and CEO of Xylem. “We have a responsibility to make a difference, working alongside our customers and partners, and the communities we all serve. That’s why our sustainability report is more than a set of numbers. It’s a report card on the difference we’re

H.I.G. Capital Expands Its Capital Formation Middle East Team with the Addition of Oliver Slade26.5.2022 12:00:00 CEST | Press release

H.I.G. Capital, LLC ("H.I.G."), a leading global alternative investment firm with over $49 billion of capital under management, is pleased to announce that Oliver Slade has joined the firm’s Capital Formation Group, as a Managing Director, based in Dubai. Oliver will be responsible for capital raising and investor relations activities in the Middle East. He has been based in the region since 2008 and has over 17 years of experience in alternative assets. Oliver joins H.I.G. from Partners Group, where he was the Head of Middle East and Africa, responsible for the development and capital raising activities across private markets funds and solutions in the region. Prior to Partners Group, Oliver held a similar role at GAM investments. Jordan Peer Griffin, Executive Managing Director and Global Head of Capital Formation, commented: “We are delighted to welcome Oliver to H.I.G. Given his experiences in the region, Oliver is a key addition to establish a local presence in the Middle East, wh

SCREEN Increases Efforts to Reduce the Environmental Impact of the Semiconductor Industry26.5.2022 10:43:00 CEST | Press release

SCREEN Semiconductor Solutions Co., Ltd. (SCREEN SPE), a subsidiary of SCREEN Holdings Co., Ltd., has announced it will increase its efforts to reduce the company’s environmental overall impact. The SCREEN Group is committed to both achieving a sustainable global society and to improving its sustainable value (social value) and has formulated a medium-term management plan titled Sustainable Value 2023 targeting these goals. The plan identifies specific issues in each of the environmental, social, and governance (ESG) fields. Concerning the environment, SCREEN is working to provide products and services that actively contribute to the reduction of ecological burden. Its efforts include improving the environmental performance of its products, reducing the effects of its business activities on climate change, promoting effective utilization of water resources, increasing recycling of products and parts, and helping to preserve biodiversity. Concretely, SCREEN SPE seeks to reduce the impac

CARVYKTI ® (ciltacabtagene autoleucel) Granted Conditional Approval by the European Commission for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma26.5.2022 09:10:00 CEST | Press release

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that the European Commission (EC) has granted conditional marketing authorization of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. Legend Biotech entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc. (Janssen) to develop and commercialize cilta-cel in December 2017. CARVYKTI® is a chimeric antigen receptor T-cell (CAR-T) therapy featuring two B-cell maturation antigen (BCMA)-targeting single domain antibodies.1 CAR-T therapy is specifically developed